Home Home Home Inbox Home Search

Event

Benralizumab Improves Morning Peak Expiratory Flow While Reducing Oral Corticosteroid Dosages for Patients with Severe, Uncontrolled Asthma in the ZONDA Phase III Trial [Board No. 410]

Location: Board no. 410
Session Type: RAPiD: Rapid Abstract Poster Discussion Session
Sunday
May
20
2:15 PM
4:15 PM

Speaker(s)/Author(s)

Mitchell Goldman

MD, PhD
AstraZeneca

James G. Zangrilli

MD
AstraZeneca

Ian Hirsch

PhD
AstraZeneca

Frank Trudo

MD, MBA
AstraZeneca

Njira Lugogo

MD
University of Michigan Medical Center

Joel N. Kline

MD
Univ of Iowa Hosp & Clinics;University of Iowa Carver College of Medicine

View Abstract

Benralizumab Improves Morning Peak Expiratory Flow While Reducing Oral Corticosteroid Dosages for Patients with Severe, Uncontrolled Asthma in the ZONDA Phase III Trial

Parent Sessions

  • A101 - MECHANISMS AND CLINICAL FEATURES OF SEVERE ASTHMA...
    05-20-2018 2:15 PM - 4:15 PM
    • Home Home Home Inbox Home Search